Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of KVD818 in healthy volunteers

Trial Profile

Phase 1 study of KVD818 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KVD 818 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 14 Sep 2017 According to a KalVista Pharmaceuticals media released, the company is about to complete this trial and plans to evaluate the final data.
    • 01 Sep 2016 New trial record
    • 11 Aug 2016 According to KalVista media release, company announced the dosing of first patient in this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top